Literature DB >> 7897050

Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales.

D Watson1, K Weber, J S Assenheimer, L A Clark, M E Strauss, R A McCormick.   

Abstract

L.A. Clark and D. Watson (1991) proposed a tripartite model that groups symptoms of depression and anxiety into 3 subtypes: symptoms of general distress that are largely nonspecific, manifestations of somatic tension and arousal that are relatively unique to anxiety, and symptoms of anhedonia and low Positive Affect that are specific to depression. This model was tested in 5 samples (3 student, 1 adult, and 1 patient sample) using the Mood and Anxiety Symptom Questionnaire (MASQ; D. Watson & L. A. Clark, 1991), which was designed to assess the hypothesized symptom groups, together with other symptom and cognition measures. Consistent with the tripartite model, the MASQ Anxious Arousal and Anhedonic Depression scales both differentiated anxiety and depression well and also showed excellent convergent validity. Thus, differentiation of these constructs can be improved by focusing on symptoms that are relatively unique to each.

Entities:  

Mesh:

Year:  1995        PMID: 7897050     DOI: 10.1037//0021-843x.104.1.3

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  367 in total

1.  Emotional conditions disrupt behavioral control among individuals with dysregulated personality traits.

Authors:  Jenessa Sprague; Edelyn Verona
Journal:  J Abnorm Psychol       Date:  2010-05

Review 2.  Well-being and affective style: neural substrates and biobehavioural correlates.

Authors:  Richard J Davidson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-09-29       Impact factor: 6.237

3.  Temporal patterns of anxious and depressed mood in generalized anxiety disorder: a daily diary study.

Authors:  Lisa R Starr; Joanne Davila
Journal:  Behav Res Ther       Date:  2011-12-07

4.  Neural inhibition enables selection during language processing.

Authors:  Hannah R Snyder; Natalie Hutchison; Erika Nyhus; Tim Curran; Marie T Banich; Randall C O'Reilly; Yuko Munakata
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-02       Impact factor: 11.205

5.  Optimizing efficiency of psychopathology assessment through quantitative modeling: development of a brief form of the Externalizing Spectrum Inventory.

Authors:  Christopher J Patrick; Mark D Kramer; Robert F Krueger; Kristian E Markon
Journal:  Psychol Assess       Date:  2013-12

6.  Electroencephalography Source Functional Connectivity Reveals Abnormal High-Frequency Communication Among Large-Scale Functional Networks in Depression.

Authors:  Alexis E Whitton; Stephanie Deccy; Manon L Ironside; Poornima Kumar; Miranda Beltzer; Diego A Pizzagalli
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-07-13

7.  Primary and Secondary Variants of Psychopathy in a Volunteer Sample Are Associated With Different Neurocognitive Mechanisms.

Authors:  Arjun Sethi; Eamon McCrory; Vanessa Puetz; Ferdinand Hoffmann; Annchen R Knodt; Spenser R Radtke; Bartholomew D Brigidi; Ahmad R Hariri; Essi Viding
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-04-12

8.  Beclomethasone-induced vasoconstriction in women with major depressive disorder.

Authors:  Nick J Coupland; Kathleen M Hegadoren; Jessica Myrholm
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

9.  Rumination and Excessive Reassurance Seeking: Investigation of the Vulnerability Model and Specificity to Depression.

Authors:  Caroline W Oppenheimer; Jessica Technow; Benjamin L Hankin; Jami F Young; John R Z Abela
Journal:  Int J Cogn Ther       Date:  2012-09-01

10.  Dimensions in major depressive disorder and their relevance for treatment outcome.

Authors:  Elske Vrieze; Koen Demyttenaere; Ronny Bruffaerts; Dirk Hermans; Diego A Pizzagalli; Pascal Sienaert; Titia Hompes; Peter de Boer; Mark Schmidt; Stephan Claes
Journal:  J Affect Disord       Date:  2013-10-19       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.